Letolizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Letolizumab
Monoclonal antibody
Type Single-chain variable fragment
Source Humanized (from mouse)
Target tumor necrosis factor related activation protein
Clinical data
Synonyms BMS-986004
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C1734H2688N466O538S10
Molar mass 39.0 g/mol

Letolizumab (INN[1]) (BMS-986004) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.

This drug was developed by Bristol-Myers Squibb.[2]

References[edit]